Isaura Araceli has completed her studies in medicine, masters and phD in from Universidad de Guadalajara, she has been certified before the Mexican council of human genetics as a clinical geneticist. Is the director of GENERA, a company dedicated to provide corporate services of high medical specialty in the area of human genetics. She has published in reputed journals about genetics diseases, has taught at the Autonomous University of Guadalajara, where she is a research professor and member of the research committee, also has taught at the UNIVA University in master in clinical nutrition. Serves patients of genetic diseases, is voluntary in the association of patients "brothers with hemophilia" and is member of the national system of researchers.

genetic diseases

Daniel Uribe, MBA, CEO & Co Founder of Genobank.io, Serial Entrepreneur, Angel Investor,+15 years of experience in Cybersecurity, Cloud Computing; +4 years of experience in Blockchain & Bioinformatics. Recently specializes in Bioethics, Genomic & Healthcare Data. He Holds a Bs. Electronics Engineering, MBA from IPADE Business School, Executive Programs in Stanford GSB, Singularity University, Data Science at Galvanize, Digital Marketing at General Assembly & RNAseq at EcSeq Bioinformatics GmbH (Berlin).

Decentralized Privacy-preserving technologies for Genomic Data

Currently working at The Chinese University of Hong Kong. And done Ph. D. Chinese Academy of Sciences M. Sc. Northeast Agricultural University B. Sc. Northeast Agricultural University

RF, Probing the molecular function of a bHLH protein in A.annua glandular trichome morphogenesis. An Integrated Functional Genomics Approach towards the Understanding of Artemisinin Metabolism.

I am Dr. Mojtaba Mafi M.D., Medical Doctor/ Physician, Graduate of Tehran university, School of Medicine with honor. I passed post graduate courses on Nutrition, Gastroenterology and hepatology, Obesity treatment and diabetes approved by Medical sciences university successfully.I am associate of Iran Hepatitis Network and Gastroenterology and Hepatology research center, Middle East Liver Diseases Center (MELD). I studied on fatty liver and related metabolic disorders among Iranian families from 2015 and currently publishing the results of our study and research about fatty liver and hyperlipidemia, diabetes and nutrition as study director and clinician associate member of Hepatitis Network.

Gastroenterology,Hepatology

John D. Loike, PhD serves as Director for Special Programs for the Center for Bioethics and is the Co-Director for Graduate Studies in the Department of Physiology and Cellular Biophysics at Columbia University College of Physicians and Surgeons. He is also an Advisory Board member of the Columbia University Center for the Study of Science and Religion, creator and faculty editor of the Columbia University Journal of Bioethics, and course instructor for Crossroads in Bioethics, a course for undergraduates offered each spring at Columbia College. He has co-organized several national and international conferences on genetics and Bioethics, and he is the founding co-director of BIOCEP (BIOethical Cross-cultural Education Program), a two-week intensive summer internship program designed to promote educational and cultural exchange in medical ethics (medical tourism, emerging infections, stem cell research, reproductive medicine, etc.) with students from Mahidol University in Bangkok, Thailand.

Dr. Loike’s areas of interest in bioethics include stem cells, cloning, neuroethics, bioterrorism, and the interface of science and religion.

Dr. Michael Nova is the Chief Innovation Officer and founding team member of Pathway Genomics. He is the inventor of all wellness genetic tests, and also the Pathway-IBM/Watson mobile application: OME. His scientific career began at the Salk Institute with Nobel Laureate Roger Guillemin, researching the genetics of growth factors. Michael was the founder/CEO of wireless drug discovery company Discovery Partners Inc. (Nasdaq: DPII; $150M IPO). Dr. Nova is an IBM and Metagenics Advisory Board Member; the 2005 World Economic Forum (WEF) Technology Pioneer Award Winner; and the physician of record on the first person to have their entire genome sequenced by Illumina (2009). He has 35 issued patents, and likes to surf in Indonesia.

Type 2 diabetes (T2D) and obesity are complex disorders that constitute major public health problems. The evidence for familial aggregation of both T2D and obesity is substantial. To date, more than 150 genetic loci are associated with the development of monogenic, syndromic, or multifactorial forms of T2D or obesity; many within lipid and carbohydrate metabolism pathways. SNPs located in or near FTO, MC4R, MC3R, POMC, LEP, LEPR, PLIN1, APOA5, LIPC, FABP2, INSIG2, IRS1, GIPR, ADBR2, ADRB3, UCP1, RETN, ADIPOQ, IL6, PPARG, TCF7L2, and CLOCK, among others, are implicated in both diabetes and obesity gene networks, pleomorphic with nutritional and metabolic traits. A personalized nutritional approach, based not only on phenotypic traits but also on genetic make-up, may help to control body weight and obesity. Recent advances in nutrigenetics, bioinformatics and genome-wide association metabolomics studies are set to unleash a revolution in personalized nutrition. In this symposium, we discuss the evidence concerning the genetic contribution to individual risk of T2D and obesity, and explore the potential role of nutritional and environmental mechanisms.

Dr. Timothy J. Miller, also known as Tim, Ph.D, has been Chief Executive Officer and President of Abeona Therapeutics Inc. formerly known as PlasmaTech Biopharmaceuticals, Inc. since May 15, 2015. ... Dr. Miller was President and Chief Executive Officer of Red5 from 2013 to 2015.

Human genetics

Dr. Dharambir Sanghera’s research specializes in the study of molecular and genetic-epidemiological aspects of common complex diseases, including diabetes, coronary heart disease, obesity, and metabolic syndrome. Using expertise in wide range of molecular and statistical genetics concepts, her laboratory is studying the interplay between environmental and genetic factors involved in complex disease pathogenesis on family- and population-based datasets. The long-term goals of Dr. Sanghera’s research are; 1) to identify the underlying molecular mechanisms associated with cardiovascular disorders, 2) to improve the classification of the disease process by identifying genome-wide patterns associated with ethnic variation, and 3) to discover new therapeutic targets which can inform the design of early prevention and treatment therapy among disparate populations

Molecular and genetic-epidemiological aspects of common complex diseases

to be updated soon

Rare genetic diseases